GLP-1R works through the combination of the endogenous ligand Glucagon-like peptide-1 (GLP-1) or exogenous agonists, which activate multiple intracellular signaling pathways that enhance insulin secretion, inhibit glucagon secretion, protect -cells from apoptosis, delay gastric emptying and increase satiety
Legislation limits the information we can share
For example, patients who had a GLP-1 receptor agonist might have had better access to medicines or healthcare than those who had non-GLP-1 receptor agonist, or they might be inherently more health conscious or healthier. He also pointed out that many of the randomized controlled trials (RCTs) in the current analysis did not have a long follow-up time, which limits the ability to detect cancer occurrences
They might even trigger hypoglycemiaa potentially life-threatening condition where blood sugar drops too low
Chen X, Maniotis A, Majumdar D, et al